Liver Tumors II: Malignant Tumors of the Liver

  • Naoshi NishidaEmail author
  • Ryuichi Kita
  • Kenichi Miyoshi
  • Masahiko Koda
  • Masaki Iwai
  • Arief A. Suriawinata


Primary liver tumors originate from hepatocytes, cholangiocytes, and mesenchymal cells (Table 17.1). Among liver tumors, hepatocellular carcinoma (HCC) is the most common; the majority of HCC develops as a result of chronic liver diseases that cause severe hepatocyte damage and regeneration. Chronic inflammation results in the formation of regenerative nodules as well as in the development of HCC through induction of many genetic/epigenetic alterations. Practitioners should attempt to differentiate HCC from benign and other malignant tumors and to treat it accordingly. Antiviral treatment for chronic hepatitis B (HBV) or C viruses (HCV) could reduce the risk of HCC emergence related to hepatitis virus [1, 2].


Malignant liver tumor Hepatocellular carcinoma Cholangiocellular carcinoma Liver sarcoma Diagnosis Treatment Tumor marker Imagining Mutation 





AT-rich interactive domain-containing protein 1A


Barcelona clinic liver cancer


Cholangiocellular carcinoma


Contract-enhanced US




Cholangiolocellular carcinoma


Computed tomography


CT arteriography


CT arterial portography


Zeste homolog 2


Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid


Gd-EOB-DTPA-enhanced MRI


Hepatic arterial infusion chemotherapy


Hepatitis B virus


Hepatocellular carcinoma


Hepatitis C virus


Magnetic resonance imaging


Neuroendocrine cancer


Neuroendocrine neoplasm


Neuroendocrine tumor


Organic anion transporting polypeptide


Percutaneous ethanol injection


Prothrombin induced by vitamin K absence-II


Performance status


Percutaneous transhepatic cholangiography


Radiofrequency ablation


Space-occupying lesion


Transarterial chemoembolization


Ten-eleven translocation methylcytosine dioxygenase 1





We are grateful to Prof. Alex Y. Chang for constructive advice for first edition of this chapter.


  1. 1.
    Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57:399–408.CrossRefGoogle Scholar
  2. 2.
    Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–37.CrossRefGoogle Scholar
  3. 3.
    Idilman R, De Maria N, Colantoni A, Van Thiel DH. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J Viral Hepat. 1998;5:285–99.CrossRefGoogle Scholar
  4. 4.
    Wogan GN. Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res. 1992;52:2114s–8s.PubMedGoogle Scholar
  5. 5.
    International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49:658–64.CrossRefGoogle Scholar
  6. 6.
    Peng SY, Lai PL, Chu JS, Lee PH, Tsung PT, Chen DS, Hsu HC. Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas. Hepatology. 1993;17:35–41.CrossRefGoogle Scholar
  7. 7.
    Aoyagi Y, Saitoh A, Suzuki Y, Igarashi K, Oguro M, Yokota T, Mori S, et al. Fucosylation index of alpha-fetoprotein, a possible aid in the early recognition of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 1993;17:50–2.CrossRefGoogle Scholar
  8. 8.
    Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Takasaki K, Takenami K, et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer. 2000;88:544–9.CrossRefGoogle Scholar
  9. 9.
    Bottelli R, Tibballs J, Hochhauser D, Watkinson A, Dick R, Burroughs AK. Ultrasound screening for hepatocellular carcinoma (HCC) in cirrhosis: the evidence for an established clinical practice. Clin Radiol. 1998;53:713–6.CrossRefGoogle Scholar
  10. 10.
    Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med. 2001;20:99–104.CrossRefGoogle Scholar
  11. 11.
    Kudo M. The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol. 2010;25:439–52.CrossRefGoogle Scholar
  12. 12.
    Kuszyk BS, Bluemke DA, Urban BA, Choti MA, Hruban RH, Sitzmann JV, Fishman EK. Portal-phase contrast-enhanced helical CT for the detection of malignant hepatic tumors: sensitivity based on comparison with intraoperative and pathologic findings. AJR Am J Roentgenol. 1996;166:91–5.CrossRefGoogle Scholar
  13. 13.
    Ward J, Guthrie JA, Scott DJ, Atchley J, Wilson D, Davies MH, Wyatt JI, et al. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology. 2000;216:154–62.CrossRefGoogle Scholar
  14. 14.
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.CrossRefGoogle Scholar
  15. 15.
    Vilgrain V, Van Beers BE, Pastor CM. Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI. J Hepatol. 2016;64:708–16.CrossRefGoogle Scholar
  16. 16.
    Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–53.CrossRefGoogle Scholar
  17. 17.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.CrossRefGoogle Scholar
  18. 18.
    Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.CrossRefGoogle Scholar
  19. 19.
    Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.CrossRefGoogle Scholar
  20. 20.
    Ishii H, Okada S, Okusaka T, Yoshimori M, Nakasuka H, Shimada K, Yamasaki S, et al. Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol injection. Cancer. 1998;82:1638–42.CrossRefGoogle Scholar
  21. 21.
    Kudo M. A new era of systemic therapy for hepatocellular carcinoma with regorafenib and lenvatinib. Liver Cancer. 2017;6:177–84.CrossRefGoogle Scholar
  22. 22.
    Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168–79.CrossRefGoogle Scholar
  23. 23.
    Shiota K, Taguchi J, Nakashima O, Nakashima M, Kojiro M. Clinicopathologic study on cholangiolocellular carcinoma. Oncol Rep. 2001;8:263–8.PubMedGoogle Scholar
  24. 24.
    Theise ND, Yao JL, Harada K, Hytiroglou P, Portmann B, Thung SN, Tsui W, et al. Hepatic ‘stem cell’ malignancies in adults: four cases. Histopathology. 2003;43:263–71.CrossRefGoogle Scholar
  25. 25.
    Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology. 2018;68(1):113–26.CrossRefGoogle Scholar
  26. 26.
    Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol. 2002;17:1049–55.CrossRefGoogle Scholar
  27. 27.
    Koga A, Ichimiya H, Yamaguchi K, Miyazaki K, Nakayama F. Hepatolithiasis associated with cholangiocarcinoma. Possible etiologic significance. Cancer. 1985;55:2826–9.CrossRefGoogle Scholar
  28. 28.
    Bloustein PA. Association of carcinoma with congenital cystic conditions of the liver and bile ducts. Am J Gastroenterol. 1977;67:40–6.PubMedGoogle Scholar
  29. 29.
    Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–25.CrossRefGoogle Scholar
  30. 30.
    Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7:1116–35.CrossRefGoogle Scholar
  31. 31.
    Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003–10.CrossRefGoogle Scholar
  32. 32.
    Nakanuma Y, Miyata T, Uchida T. Latest advances in the pathological understanding of cholangiocarcinomas. Expert Rev Gastroenterol Hepatol. 2016;10:113–27.CrossRefGoogle Scholar
  33. 33.
    Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–89.CrossRefGoogle Scholar
  34. 34.
    Akwari OE, Tucker A, Seigler HF, Itani KM. Hepatobiliary cystadenoma with mesenchymal stroma. Ann Surg. 1990;211:18–27.CrossRefGoogle Scholar
  35. 35.
    Vachha B, Sun MR, Siewert B, Eisenberg RL. Cystic lesions of the liver. AJR Am J Roentgenol. 2011;196:W355–66.CrossRefGoogle Scholar
  36. 36.
    Shrikhande S, Kleeff J, Adyanthaya K, Zimmermann A, Shrikhande V. Management of hepatobiliary cystadenocarcinoma. Dig Surg. 2003;20:60–3.CrossRefGoogle Scholar
  37. 37.
    Bortolasi L, Marchiori L, Dal Dosso I, Colombari R, Nicoli N. Hepatoblastoma in adult age: a report of two cases. Hepatogastroenterology. 1996;43:1073–8.PubMedGoogle Scholar
  38. 38.
    King SJ, Babyn PS, Greenberg ML, Phillips MJ, Filler RM. Value of CT in determining the resectability of hepatoblastoma before and after chemotherapy. AJR Am J Roentgenol. 1993;160:793–8.CrossRefGoogle Scholar
  39. 39.
    Gonzalez-Crussi F, Upton MP, Maurer HS. Hepatoblastoma. Attempt at characterization of histologic subtypes. Am J Surg Pathol. 1982;6:599–612.CrossRefGoogle Scholar
  40. 40.
    Kremer N, Walther AE, Tiao GM. Management of hepatoblastoma: an update. Curr Opin Pediatr. 2014;26:362–9.CrossRefGoogle Scholar
  41. 41.
    Malamut G, Perlemuter G, Buffet C, Bedossa P, Joly JP, Colombat M, Kuoch V, et al. [Epithelioid hemangioendothelioma associated with nodular regenerative hyperplasia]. Gastroenterol Clin Biol. 2001;25:1105–7.Google Scholar
  42. 42.
    Demetris AJ, Minervini M, Raikow RB, Lee RG. Hepatic epithelioid hemangioendothelioma: biological questions based on pattern of recurrence in an allograft and tumor immunophenotype. Am J Surg Pathol. 1997;21:263–70.CrossRefGoogle Scholar
  43. 43.
    Kayler LK, Merion RM, Arenas JD, Magee JC, Campbell DA, Rudich SM, Punch JD. Epithelioid hemangioendothelioma of the liver disseminated to the peritoneum treated with liver transplantation and interferon alpha-2B. Transplantation. 2002;74:128–30.CrossRefGoogle Scholar
  44. 44.
    Chaudhary P, Bhadana U, Singh RA, Ahuja A. Primary hepatic angiosarcoma. Eur J Surg Oncol. 2015;41:1137–43.CrossRefGoogle Scholar
  45. 45.
    Falk H, Thomas LB, Popper H, Ishak KG. Hepatic angiosarcoma associated with androgenic-anabolic steroids. Lancet. 1979;2:1120–3.CrossRefGoogle Scholar
  46. 46.
    Cadranel JF, Legendre C, Desaint B, Delamarre N, Florent C, Levy VG. Liver disease from surreptitious administration of urethane. J Clin Gastroenterol. 1993;17:52–6.CrossRefGoogle Scholar
  47. 47.
    Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25:186–92.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Naoshi Nishida
    • 1
    Email author
  • Ryuichi Kita
    • 2
  • Kenichi Miyoshi
    • 3
  • Masahiko Koda
    • 3
  • Masaki Iwai
    • 4
  • Arief A. Suriawinata
    • 5
  1. 1.OsakaJapan
  2. 2.OsakaJapan
  3. 3.TottoriJapan
  4. 4.KyotoJapan
  5. 5.New HampshireUSA

Personalised recommendations